Many people with type 2 diabetes require two or three medications to reach this target, yet Retatrutide achieved this in the vast majority of trial participants as a single agent
[DOI] [PMC free article] [PubMed] [Google Scholar] [54].Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK
Before your first fill, it's worth asking three questions: Which GLP-1 does your plan favor
While the ADA recommends considering a GLP-1 receptor agonist or the addition of mealtime insulin, 3 the AACE/ACE algorithm additionally recommends SGLT-2 inhibitors and DPP-4 inhibitors as potential therapies that can be added to basal insulin, if they are not already incorporated into the medication regimen